Front-line paclitaxel–vinorelbine versus paclitaxel–carboplatin in patients with advanced non-small-cell lung cancer: a randomized phase III trial

Stathopoulos, George P.; Veslemes, M.; Georgatou, Niki; Antoniou, D.; Giamboudakis, P.; Katis, K.; Tsavdaridis, D.; Rigatos, Sotiris K.; Dimitroulis, J.; Bastani, S.; Loukides, Stelios; Vergos, K.; Marossis, K.; Grigoratou, T.; Kalatzi, E.; Charalambatou, M.; Paspalli, A.; Michalopoulou, P.; Stoka, M.; Gerogianni, Aleka

doi:10.1093/annonc/mdh260

Cited by 55 publications

(33 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The proportion of males varied within the range of 51%-93%. Most patients had stage IIIB or IV NSCLC; inoperable stage IIIA disease was also admitted in three studies [35,45,62], whereas stage IIIB disease was excluded in one trial [47].…”

Section: Patient Characteristicsmentioning

confidence: 99%

“…Reasons for exclusion were not stated in eight studies [30,31,40,42,43,48,57,64], whereas we were unable to assess if any exclusion criteria were applied in a trial published in Chinese only [46]. Response was assessed according to the World Health Organization standard criteria [72] in 19 trials [22,23,25,29,32,34,35,39,44,45,47,49,50,52,53,59,62,65,68], according to the Southwest Oncology Group guidelines [73] in two studies [21,24], and according to the Response Evaluation Criteria in Solid Tumors [74] in four trials [60,61,66,67].…”

Section: Patient Characteristicsmentioning

confidence: 99%

See 1 more Smart Citation

Impact of Third-Generation Drugs on the Activity of First-Line Chemotherapy in Advanced Non-Small Cell Lung Cancer: A Meta-Analytical Approach

Grossi¹,

Aita²,

Defferrari³

et al. 2009

The Oncologist

View full text Add to dashboard Cite

Background. The therapeutic equivalence of different third-generation agents in the first-line treatment of advanced non-small cell lung cancer (NSCLC) has long been accepted, although recent studies seem to suggest some superiority of gemcitabine-or docetaxel-containing regimens over other third-generation doublets.Objective. To assess the relative impact of different third-generation drugs on the activity of first-line chemotherapy in advanced non-small cell lung cancer by considering both response and progressive disease (PD) rates as outcome measures.Methods. Published and unpublished data were collected from randomized trials comparing a gemcitabine-, docetaxel-, vinorelbine-or paclitaxel-containing regimen with one or more gemcitabine-, docetaxel-, vinorelbine-or paclitaxel-free combinations. For

show abstract

Section: Patient Characteristicsmentioning

confidence: 99%

Section: Patient Characteristicsmentioning

confidence: 99%

Impact of Third-Generation Drugs on the Activity of First-Line Chemotherapy in Advanced Non-Small Cell Lung Cancer: A Meta-Analytical Approach

Grossi¹,

Aita²,

Defferrari³

et al. 2009

The Oncologist

View full text Add to dashboard Cite

show abstract

“…Paclitaxel was given biweekly (once every 2 weeks) at a dose of 135 mg m À2 , in combination with a second agent, and toxicity was well-tolerated (Stathopoulos et al, 2004). The dose of irinotecan combined with another agent, administered on days 1 and 8, repeated every 21 days, varied from 60 to 110 mg m À2 (Kakolyris et al, 2000(Kakolyris et al, , 2001Keresztes et al, 2004).…”

Section: Treatment Planmentioning

confidence: 99%

“…We intended to increase the latter to a higher dose if it was well tolerated. The dose of paclitaxel remained at 135 mg m À2 , as this had been tested in a biweekly administration in combination with other myelotoxic agents such as carboplatin or navelbine (Stathopoulos et al, 2004). Table 1 shows dose escalation.…”

Section: Treatment Planmentioning

confidence: 99%

“…Existing data combining irinotecan with other agents such as cisplatin (Cardenal et al, 2003) show an effectiveness comparable to other established treatments in NSCLC (Negoro et al, 2003). For the present study, the second agent selected for combination treatment with irinotecan was paclitaxel, which has been tested as first-line combined treatment for advanced NSCLC (Chang et al, 1996;Greco and Hainsworth, 1997;Belani et al, 1999;Bonomi et al, 2000;Stathopoulos et al, 2004). In vitro combination studies of topoisomerase inhibitors with taxanes have shown conflicting results.…”

mentioning

confidence: 91%

See 1 more Smart Citation

Front-line paclitaxel and irinotecan combination chemotherapy in advanced non-small-cell lung cancer: a phase I–II trial

et al. 2005

View full text Add to dashboard Cite

Our purpose was to determine the efficacy of irinotecan plus paclitaxel administered on day 1, repeated every 2 weeks, in untreated patients with advanced or metastatic non-small-cell lung cancer (NSCLC). In total, 56 patients with inoperable or metastatic stage III and IV NSCLC with a histologically or cytologically confirmed diagnosis were enrolled. None of the patients had undergone prior chemotherapy or radiation therapy. Treatment involved irinotecan 125 mg m À2 and paclitaxel 135 mg m À2 administered on day 1 and repeated every 2 weeks for a planned number of nine cycles. With a standard dose of paclitaxel at 135 mg m À2 , the dosage of irinotecan was escalated at four levels: 75, 100, 125 and 150 mg m À2 ; 125 mg m À2 was established as the maximum tolerated dose; this dosage was administered to 46 patients. A total of 52 patients (median age 65 years, range 38 -77 years) were assessable for toxicity and survival and 46 for response rate. Out of 46 evaluable patients, 19 achieved partial response (41.3%), 17 had stable disease (37%) and 10 (21.7%) experienced disease progression. The median duration of response was 6 months (range 2 -9 þ months). The main adverse reactions were myelotoxicity (grades 3 and 4) in 10 (19.2%) patients and diarrhoea (grade 3) in four (7.7%) patients. Irinotecan combined with paclitaxel, administered every 2 weeks, appears to be an effective treatment for advancedstage NSCLC.

show abstract

Chemotherapy for advanced non-small cell lung cancer in the elderly population

Santos

Castria

Cruz

et al. 2015

Cochrane Database of Systematic Reviews

View full text Add to dashboard Cite

BACKGROUND: Approximately 50% of patients with newly diagnosed non-small cell lung cancer (NSCLC) are over 70 years of age at diagnosis. Despite this fact, these patients are underrepresented in randomized controlled trials (RCTs). As a consequence, the most appropriate regimens for these patients are controversial, and the role of single-agent or combination therapy is unclear. In this setting, a critical systematic review of RCTs in this group of patients is warranted. OBJECTIVES: To assess the effectiveness and safety of different cytotoxic chemotherapy regimens for previously untreated elderly patients with advanced (stage IIIB and IV) NSCLC. To also assess the impact of cytotoxic chemotherapy on quality of life. METHODS: Search methods: We searched the following electronic databases: Cochrane Central Register of Controlled Trials (CENTRAL; 2014, Issue 10),

show abstract

Front-line paclitaxel–vinorelbine versus paclitaxel–carboplatin in patients with advanced non-small-cell lung cancer: a randomized phase III trial

Abstract: PCT combined with VRL produces similar (non-significant) response rates, survival and toxicity (except for neutropenia, as noted above) to standard CRP-PCT treatment in untreated advanced-stage NSCLC.

Cited by 55 publications

References 38 publications

Impact of Third-Generation Drugs on the Activity of First-Line Chemotherapy in Advanced Non-Small Cell Lung Cancer: A Meta-Analytical Approach

Impact of Third-Generation Drugs on the Activity of First-Line Chemotherapy in Advanced Non-Small Cell Lung Cancer: A Meta-Analytical Approach

Front-line paclitaxel and irinotecan combination chemotherapy in advanced non-small-cell lung cancer: a phase I–II trial

Chemotherapy for advanced non-small cell lung cancer in the elderly population

Contact Info

Product

Resources

About